Show simple item record

dc.contributor.authorHagemo, Jostein Skjalg
dc.contributor.authorSkulberg, Arne Kristian
dc.contributor.authorRehn, Marius
dc.contributor.authorValberg, Morten
dc.contributor.authorPesonen, Maiju
dc.contributor.authorHeimdal, Hans Julius
dc.contributor.authorHeyerdahl, Fridtjof
dc.date.accessioned2023-03-02T10:16:26Z
dc.date.available2023-03-02T10:16:26Z
dc.date.created2022-09-01T13:14:48Z
dc.date.issued2022
dc.identifier.citationPLOS ONE. 2022, 17 (5), .en_US
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/11250/3055265
dc.description.abstractBackground In March 2020, WHO announced the COVID-19 a pandemic and a major global public health emergency. Mortality from COVID-19 is rapidly increasing globally, with acute respiratory failure as the predominant cause of death. Many patients experience severe hypoxia and life-threatening respiratory failure often requiring mechanical ventilation. To increase safety margins during emergency anaesthesia and rapid sequence intubation (RSI), patients are preoxygenated with a closed facemask with high-flow oxygen and positive end-expiratory pressure (PEEP). Due to the high shunt fraction of deoxygenated blood through the lungs frequently described in COVID-19 however, these measures may be insufficient to avoid harmful hypoxemia. Preoxygenation with inhaled nitric oxide (iNO) potentially reduces the shunt fraction and may thus allow for the necessary margins of safety during RSI. Methods and design The INOCOV protocol describes a phase II pharmacological trial of inhaled nitric oxide (iNO) as an adjunct to standard of care with medical oxygen in initial airway and ventilation management of patients with known or suspected COVID-19 in acute respiratory failure. The trial is parallel two-arm, randomized, controlled, blinded trial. The primary outcome measure is the change in oxygen saturation (SpO2), and the null hypothesis is that there is no difference in the change in SpO2 following initiation of iNO. Trial registration EudraCT number 2020-001656-18; WHO UTN: U1111-1250-1698. Protocol version: 2.0 (June 25th, 2021).en_US
dc.language.isoengen_US
dc.publisherPLOSen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleInhaled nitric oxide as temporary respiratory stabilization in patients with COVID-19 related respiratory failure (INOCOV): Study protocol for a randomized controlled trialen_US
dc.title.alternativeInhaled nitric oxide as temporary respiratory stabilization in patients with COVID-19 related respiratory failure (INOCOV): Study protocol for a randomized controlled trialen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber0en_US
dc.source.volume17en_US
dc.source.journalPLOS ONEen_US
dc.source.issue5en_US
dc.identifier.doi10.1371/journal.pone.0268822
dc.identifier.cristin2047881
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal